SHINE Technologies’ production process results in molybdenum-99 that is of high quality and high purity, resulting in Mo-99 that has high specific activity and is ready for delivery to our medical customers. We believe our production of Mo-99 in the United States will contribute to the reliability of SHINE’s supply in a time of chronic shortages of medical isotopes.
Mo‑99 is the parent isotope of technetium–99m, a light-emitting element that is administered to tens of thousands of Americans every day for the purpose of diagnosing and staging a multitude of diseases, including cancer and heart disease.
SHINE will produce Mo‑99, which is then loaded into Tc‑99m generators. As Mo‑99 turns into Tc‑99m within the generator, the Tc‑99m can be extracted by radiopharmacy staff for use in imaging procedures.